One of the largest genetic studies in the United States is set to occur over the next five years, analyzing over 100,000 patients DNA in an attempt to link genes with human diseases, disorders, and other medical conditions. The study will be run by pharmaceutical maker Regeneron in a partnership with the around three-million member Geisinger Health System. Naturally, Regeneron is looking to develop new drugs that it can market, while Geisinger is hoping to improve patient care at the individual level, as the studys large size is meant to provide a high level of precision in linking genes and diseases. The study will of course be quite expensive. The New York Times pegs the total cost as around $100 million over the course of the five-year study — though its an amount that the Times says is more than manageable for Regeneron.